Data from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

• DOI: 10.1158/1078-0432.c.6532847.v1
• Publication Date: 2023-04-01T05:59:22Z
• Authors: Funda Meric-Bernstam; Randy F. Sweis; Stefan Kasper; Omid Hamid; Shailender Bhatia; Reinhard Dummer; Agostina Stradella; Georgina V. Long; Anna Spreafico; Toshio Shimizu; Neeltje Steeghs; Jason J. Luke; Sarah M. McWhirter; Thomas Müller; Nitya Nair; Nancy Lewis; Xinhui Chen; Andrew Bean; Lisa Kattenhorn; Marc Pelletier; Shahneen Sandhu

<div>AbstractPurpose:<p>The stimulator of IFN genes (STING) is a transmembrane protein that plays a role in the immune response to tumors. Single-agent STING agonist MIW815 (ADU-S100) has demonstrated immune activation but limited antitumor activity. This phase Ib, multicenter, dose-escalation study assessed the safety and tolerability of MIW815 plus spartalizumab (PDR001), a humanized IgG4 antibody against PD-1, in 106 patients with advanced solid tumors or lymphomas.</p>Patients and Methods:<p>Patients were treated with weekly intratumoral injections of MIW815 (50–3,200 μg) on a 3-weeks-on/1-week-off schedule or once every 4 weeks, plus a fixed dose of spartalizumab (400 mg) intravenously every 4 weeks.</p>Results:<p>Common adverse events were pyrexia (<i>n</i> = 23; 22%), injection site pain (<i>n</i> = 21; 20%), and diarrhea (<i>n</i> = 12; 11%). Overall response rate was 10.4%. The MTD was not reached. Pharmacodynamic biomarker analysis demonstrated on-target activity.</p>Conclusions:<p>The combination of MIW815 and spartalizumab was well tolerated in patients with advanced/metastatic cancers, including in patients with anti-PD-1 refractory disease. Minimal antitumor responses were seen.</p></div>